# Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer

> **NCT06569459** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Trilaciclib Injection [Cosela]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06569459
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-09
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-07-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06569459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06569459, "Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06569459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*